US 11,756,778 B2
Collection probe and methods for the use thereof
Livia Schiavinato Eberlin, Austin, TX (US); Thomas Milner, Austin, TX (US); Jialing Zhang, Austin, TX (US); John Lin, Austin, TX (US); John Rector, Austin, TX (US); Nitesh Katta, Austin, TX (US); and Aydin Zahedivash, Austin, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Dec. 30, 2021, as Appl. No. 17/566,192.
Application 16/817,728 is a division of application No. 15/692,167, filed on Aug. 31, 2017, granted, now 10,643,832, issued on May 5, 2020.
Application 17/566,192 is a continuation of application No. 17/106,445, filed on Nov. 30, 2020, granted, now 11,239,065.
Application 17/106,445 is a continuation of application No. 16/817,728, filed on Mar. 13, 2020, granted, now 10,943,775, issued on Mar. 9, 2021.
Claims priority of provisional application 62/462,524, filed on Feb. 23, 2017.
Claims priority of provisional application 62/411,321, filed on Oct. 21, 2016.
Claims priority of provisional application 62/383,234, filed on Sep. 2, 2016.
Prior Publication US 2022/0310378 A1, Sep. 29, 2022
Int. Cl. H01J 49/00 (2006.01); H01J 49/04 (2006.01); A61B 10/00 (2006.01); G01N 33/487 (2006.01); B01L 3/00 (2006.01); G01N 33/68 (2006.01); G01N 1/02 (2006.01); G01N 30/72 (2006.01); G01N 33/574 (2006.01); B01L 3/02 (2006.01); G01N 1/40 (2006.01)
CPC H01J 49/0431 (2013.01) [A61B 10/0045 (2013.01); B01L 3/502 (2013.01); G01N 1/02 (2013.01); G01N 30/72 (2013.01); G01N 33/487 (2013.01); G01N 33/574 (2013.01); G01N 33/6848 (2013.01); H01J 49/0031 (2013.01); H01J 49/04 (2013.01); B01L 3/0293 (2013.01); B01L 2200/0605 (2013.01); B01L 2400/0655 (2013.01); G01N 2001/028 (2013.01); G01N 2001/4061 (2013.01); G01N 2560/00 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for assessing tissue samples from a subject, the method comprising:
(a) applying a fixed or discrete volume of a solvent to a tissue site in the subject;
(b) collecting the applied solvent to obtain a liquid sample;
(c) subjecting the liquid sample to mass spectrometry analysis, thereby obtaining a mass spectrometry profile comprising a plurality of mass-to-charge (m/z) ratios; and
(d) characterizing the liquid sample based on the mass spectrometry profile;
wherein characterizing the liquid sample comprises determining whether the tissue site comprises:
normal lung, breast, ovarian, or thyroid cells;
benign lung, breast, ovarian, or thyroid cells; or
cancerous lung, breast, ovarian, or thyroid cells;
wherein when the profile comprises at least 5 mass-to-charge (m/z) ratios selected from the group consisting of 175.02, 187.01, 201.04, 215.03, 306.08, 313.16, 330.98, 332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52, 773.53, 861.55, 863.57, 885.55, and 886.55, then the tissue site is identified as comprising cancerous lung cells;
wherein when the profile comprises at least 3 mass-to-charge (m/z) ratios selected from the group consisting of 124.01, 175.02, 175.03, 283.27, 313.16, and 341.27, then the tissue site is identified as comprising cancerous ovarian cells;
wherein when the profile comprises at least 5 mass-to-charge (m/z) ratios selected from the group consisting of 175.02, 191.02, 191.05, 283.27, 341.27, 353.16, 432.20, 433.21, 615.17, 822.47, and 822.48, then the tissue site is identified as comprising cancerous thyroid cells; and
when the profile comprises at least 5 mass-to-charge (m/z) ratios selected from the group consisting of 187.04, 268.80, 279.92, 283.27, 341.27, 345.16, 381.21, 687.51, 742.54, and 766.54, then the sample is identified as comprising cancerous breast cells.